Stelara (also known by its generic name ustekinumab) was approved by the FDA in September 2009 for the treatment of moderate-to-severe plaque psoriasis in patients ages 6 years and older. In September 2013 the FDA also approved Stelara to treat adults with active psoriatic arthritis.
Stelara is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterwards.
To learn more, please visit the Stelara website.
